午夜不卡av免费-国产在线播-亚洲精品三-亚洲一区av在线观看-香蕉视频免费在线观看-日本丰满大乳免费xxxx-天天躁夜夜躁狠狠喷水-制服 丝袜 有码 无码 中文-桃色视频.m3u8-视频一区二区欧美-亚洲第一夜页-黄色一级视屏-正在播放国产对白孕妇作爱-亚洲成人7777-日韩aⅴ在线观看-国产精品bbwbbwbbw在线-亚洲激情啪啪-ā片在线观看免费看无码-av无码爆乳护士在线播放-国产不卡视频一区二区三区

Welcome to Linuo Group!HomeBusiness License
  • CN

  • WeChat

  • Mobile Site

  • Search

力諾資訊

Keyuan Pharma Wins 2025 Forbes China Industry Development Innovative Brand Award

2025.04.02

Shandong Keyuan Pharmaceutical Co., Ltd. has been awarded the 2025 Forbes China Industry Development Innovative Brand Award at the 2025 Forbes China Industry Development Pioneers Selection held in Shanghai on March 22nd, in recognition of its exceptional innovation capabilities and significant industry influence.

The accolade not only represents high recognition of Keyuan Pharma's years of dedicated efforts in the field of chemical APIs and preparations but also stands as a powerful testament to its leapfrog development driven by innovation amid the adjustments in the global industrial landscape.

Jointly initiated by Frost & Sullivan, a world-renowned growth consulting firm, and Forbes China Group, the 2025 Forbes China Industry Development Pioneers Selection aims to identify outstanding enterprises and individuals in key sectors such as new energy, AI technology, mass consumption, and biomedicine that are driving industry transformation with an innovative spirit. Keyuan Pharma's success in standing out this time underscores its prominent position in the chemical drug sector.

Founded in 2004, Keyuan Pharmaceutical has focused on the R&D, production, and sales of chemical APIs and preparations. It has established three core product lines: anti-diabetic, cardiovascular, and anesthetic drugs, and ranks as a backbone enterprise in the field of chemical synthetic drugs in Shandong Province.

Innovation is the core driving force behind Keyuan Pharma's development. The company has continuously increased its R&D investment, actively explored cutting-edge technologies, and improved its innovation system. Recently, Keyuan Pharma obtained the utility model patent authorization for "a raw material preliminary processing and drying device for metformin hydrochloride processing," marking the fourth patent authorization it has received this year. A series of patent achievements have provided solid support for improving product quality, enhancing production efficiency, and controlling costs, helping the company gain an edge in the fierce market competition.